No, I don't have a problem with disclosure regarding Biohorizon's agreement.
First area where I think disclosure could be better....
What is the funding relationship and joint venture situation between J & J which began in 2017, especially regarding Ortho-ATI?
Does J & J still maintain an interest in the Ortho-ATI research and this technology?
Are J & J continuing to help fund the research and development of this technology?
Does J & J have first rights of refusal to buy the rights to this technology or partner with Orthocell?
Are Orthocell still able to negotiate with other interested parties?
We have no information regarding this? Surely after 6 years, Orthocell management can indicate whether they are still working together or not?
Ann: Quarterly Activity Report & Appendix 4C, page-71
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
0.010(2.63%) |
Mkt cap ! $81.63M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 39.0¢ | 37.5¢ | $49.66K | 129.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 20305 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 77938 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| OCC (ASX) Chart |